APPLIED THERAPEUTICS INC (APLT) Stock Price, Quote, News and Overview
NASDAQ:APLT - Nasdaq - US03828A1016 - Common Stock - Currency: USD
APLT Quote, Performance and Key Statistics
0.5432
+0.01 (+2.49%)
The current stock price of APLT is 0.5432 USD. In the past month the price decreased by -14.98%. In the past year, price decreased by -92.32%.
APLT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| AMGN | AMGEN INC | 15.63 | 166.32B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About APLT
Company Profile
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2019-05-09. The company is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The firm is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Company Info
APPLIED THERAPEUTICS INC
545 Fifth Avenue, Suite 1400
New York City NEW YORK 10017 US
CEO: Shoshana Shendelman
Employees: 31
Company Website: https://www.appliedtherapeutics.com/
Investor Relations: https://ir.appliedtherapeutics.com/
Phone: 12122209226
APPLIED THERAPEUTICS INC / APLT FAQ
What is the stock price of APPLIED THERAPEUTICS INC today?
The current stock price of APLT is 0.5432 USD. The price increased by 2.49% in the last trading session.
What is the ticker symbol for APPLIED THERAPEUTICS INC stock?
The exchange symbol of APPLIED THERAPEUTICS INC is APLT and it is listed on the Nasdaq exchange.
On which exchange is APLT stock listed?
APLT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APPLIED THERAPEUTICS INC stock?
12 analysts have analysed APLT and the average price target is 4.59 USD. This implies a price increase of 744.99% is expected in the next year compared to the current price of 0.5432. Check the APPLIED THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APPLIED THERAPEUTICS INC worth?
APPLIED THERAPEUTICS INC (APLT) has a market capitalization of 63.21M USD. This makes APLT a Micro Cap stock.
How many employees does APPLIED THERAPEUTICS INC have?
APPLIED THERAPEUTICS INC (APLT) currently has 31 employees.
What are the support and resistance levels for APPLIED THERAPEUTICS INC (APLT) stock?
APPLIED THERAPEUTICS INC (APLT) has a resistance level at 0.59. Check the full technical report for a detailed analysis of APLT support and resistance levels.
Is APPLIED THERAPEUTICS INC (APLT) expected to grow?
The Revenue of APPLIED THERAPEUTICS INC (APLT) is expected to decline by -95% in the next year. Check the estimates tab for more information on the APLT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy APPLIED THERAPEUTICS INC (APLT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APLT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APLT, evaluating the profitability, health, valuation and growth aspects
- APPLIED THERAPEUTICS INC (APLT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APPLIED THERAPEUTICS INC (APLT) Sales and EPS estimates to see what analysts future expectations are.
- APPLIED THERAPEUTICS INC (APLT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APPLIED THERAPEUTICS INC (APLT) Insider and Institutional Ownership to learn about the owners and their transactions.
- APPLIED THERAPEUTICS INC (APLT) Stock Chart to make your own analysis
- APPLIED THERAPEUTICS INC (APLT) Latest news and press-releases to stay up to date.
Does APPLIED THERAPEUTICS INC (APLT) stock pay dividends?
APLT does not pay a dividend.
When does APPLIED THERAPEUTICS INC (APLT) report earnings?
APPLIED THERAPEUTICS INC (APLT) will report earnings on 2025-03-14, after the market close.
What is the Price/Earnings (PE) ratio of APPLIED THERAPEUTICS INC (APLT)?
APPLIED THERAPEUTICS INC (APLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.47).
What is the Short Interest ratio of APPLIED THERAPEUTICS INC (APLT) stock?
The outstanding short interest for APPLIED THERAPEUTICS INC (APLT) is 20.72% of its float. Check the ownership tab for more information on the APLT short interest.
APLT Technical Analysis
APLT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APLT. APLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
APLT Financial Highlights
Over the last trailing twelve months APLT reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS decreased by -24.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -252.8% | ||
| ROE | -4572.2% | ||
| Debt/Equity | 0 |
APLT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to APLT. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -9.6% and a revenue growth -95% for APLT